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BACKGROUND: Long QT syndrome (LQTS) is a rare genetic disorder and a major 
preventable cause of sudden cardiac death in the young. A causal rare genetic 
variant with large effect size is identified in up to 80% of probands (genotype 
positive) and cascade family screening shows incomplete penetrance of genetic 
variants. Furthermore, a proportion of cases meeting diagnostic criteria for LQTS 
remain genetically elusive despite genetic testing of established genes (genotype 
negative). These observations raise the possibility that common genetic variants 
with small effect size contribute to the clinical picture of LQTS. This study aimed 
to characterize and quantify the contribution of common genetic variation to 
LQTS disease susceptibility.
METHODS: We conducted genome-wide association studies followed by 
transethnic meta-analysis in 1656 unrelated patients with LQTS of European or 
Japanese ancestry and 9890 controls to identify susceptibility single nucleotide 
polymorphisms. We estimated the common variant heritability of LQTS and 
tested the genetic correlation between LQTS susceptibility and other cardiac 
traits. Furthermore, we tested the aggregate effect of the 68 single nucleotide 
polymorphisms previously associated with the QT-interval in the general 
population using a polygenic risk score.
RESULTS: Genome-wide association analysis identified 3 loci associated with 
LQTS at genome-wide statistical significance (P<5×10−8) near NOS1AP, KCNQ1, 
and KLF12, and 1 missense variant in KCNE1 (p.Asp85Asn) at the suggestive 
threshold (P<10−6). Heritability analyses showed that ≈15% of variance in overall 
LQTS susceptibility was attributable to common genetic variation (h2SNP 0.148; 
standard error 0.019). LQTS susceptibility showed a strong genome-wide genetic 
correlation with the QT-interval in the general population (rg=0.40; P=3.2×10
−3). 
The polygenic risk score comprising common variants previously associated with 
the QT-interval in the general population was greater in LQTS cases compared 
with controls (P<10−13), and it is notable that, among patients with LQTS, 
this polygenic risk score was greater in patients who were genotype negative 
compared with those who were genotype positive (P<0.005).
CONCLUSIONS: This work establishes an important role for common genetic 
variation in susceptibility to LQTS. We demonstrate overlap between genetic 
control of the QT-interval in the general population and genetic factors 
contributing to LQTS susceptibility. Using polygenic risk score analyses aggregating 
common genetic variants that modulate the QT-interval in the general population, 
we provide evidence for a polygenic architecture in genotype negative LQTS.
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Long QT syndrome (LQTS) is a rare inherited disorder of ventricular repolarization characterized by pro-longation of the QT interval on the ECG.1,2 LQTS 
has a prevalence of approximately 1 in 2500, and is 
a major and often preventable cause of sudden car-
diac death in the young.3,4 Multiple genes have been 
implicated in LQTS and clinical genetic testing is now 
performed to identify causative rare genetic variants.5 
Disease-causing variants (ie, mutations) in the 3 major 
LQTS genes (ie, KCNQ1 [LQT1], KCNH2 [LQT2], and 
SCN5A [LQT3]), account for up to 80% of LQTS cases 
overall and >95% of genotype positive LQTS.2
Studies in families with multiple mutation carriers 
have shown that disease penetrance (proportion of 
carriers that manifest with a prolonged QT-interval) can 
be low,6–8 and that among those with disease mani-
festations, there can be broad variability in the types 
of symptoms and severity thereof (variable expres-
sion).2,6–8 These observations suggest that, like other 
Mendelian disorders, allocating the disease in the in-
dividual patient exclusively to a rare variant at a single 
locus (ie, monogenetic) might be an oversimplification 
of biological phenomena. It is likely that a combination 
of genetic and nongenetic modifying factors underlies 
this clinical variability. A comprehensive knowledge of 
such risk factors that affect penetrance and expressiv-
ity of disease-causing variants in LQTS will improve the 
predictive accuracy of genetic testing in the individual 
patient and enable personalized clinical interventions. 
While many clinical risk factors such as sex, hypoka-
lemia, or bradyarrhythmia, have been implicated as 
modulators of the clinical manifestations of LQTS,9 
modulatory genetic factors remain largely unexplored 
with the exception of a few proof-of-concept studies 
using a candidate gene approach.10–14
Besides variability in disease manifestations among 
carriers of pathogenic variants, an outstanding issue in 
LQTS is the fact that in ≈20% of patients, an underlying 
causal rare genetic variant remains unidentified after ex-
tensive panel-based genetic testing.15 This complicates 
cascade screening in families and the presymptomatic 
identification of affected relatives. Although a small pro-
portion of such patients with genotype negative LQTS 
could have a yet unknown Mendelian defect, another 
possibility is that a more complex inheritance pattern 
underlies the disorder in a subset of these patients.
Previous work has shown that a genome-wide as-
sociation study (GWAS) comparing cases of a rare ar-
rhythmia syndrome with unaffected controls can de-
fine modulators of disease susceptibility and suggest a 
polygenic etiology.16 We report here a GWAS in ≈1700 
unrelated patients with LQTS, of European or Japanese 
ancestry, identifying common genetic variants impli-
cated in LQTS disease susceptibility, and providing a 
quantification of the contribution of common genetic 
variants to LQTS predisposition. Using polygenic risk 
score analyses aggregating common genetic variants 
that modulate the QT-interval in the general popula-
tion, we provide evidence for a polygenic architecture 
in genotype negative LQTS.
METHODS
The summary statistics generated in this study are available from 
the corresponding author on request or on the Cardiovascular 
Disease Knowledge Portal (http://www.broadcvdi.org/).
Study Population
We established an international consortium allowing recruit-
ment of 1781 unrelated patients with LQTS: 1344 cases of 
European ancestry from 23 referral centers in Europe, New 
Zealand, and North America, as well as 437 patients of East 
Asian ancestry from 4 referral centers in Japan (Table I in the 
Data Supplement). Included unrelated individuals were pro-
bands (97%) except when DNA was not available, in which 
case 1 other affected family member was included instead. 
Included patients had a clinical diagnosis of LQTS5 and were 
classified as “genotype positive” if they carried a single rare 
variant in 1 of the 3 established major LQTS genes (KCNQ1 
[LQT1], KCNH2 [LQT2] and SCN5A [LQT3]), or “genotype 
Clinical Perspective
What Is New?
• A genome-wide association study in long QT syn-
drome (LQTS) patients establishes and quantifies 
the role of common genetic variation in suscepti-
bility to LQTS.
• Genetic overlap exists between control of QT-inter-
val in the general population and susceptibility to 
LQTS.
• Polygenic risk score analyses based on common 
genetic variants that modulate the QT-interval in 
the general population provide evidence for a poly-
genic architecture in LQTS patients that remains 
genetically elusive despite genetic testing of estab-
lished genes (ie, genotype negative).
What Are the Clinical Applications?
• These findings enhance the understanding of the 
genetic basis of LQTS and underscore the genetic 
relationship between QT-interval in the general 
population and susceptibility to LQTS.
• Increasing burden of QT-prolonging common vari-
ants is associated with higher susceptibility for LQTS.
• Polygenicity in genotype negative LQTS patients 
implies that risk is not primarily attributable to 1 
genetic factor inherited from 1 of the biological par-
ents as is the case for autosomal dominant LQTS.
• Future clinical utility of genetic testing based on poly-
genic inheritance necessitates the availability of poly-
genic risk scores with high discriminative capacity.
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negative” if no rare variant was identified in genes unequivo-
cally associated with nonsyndromic LQTS (KCNQ1, KCNH2, 
SCN5A, CALM1-3, and TRDN).17–19 A rare variant was defined 
as a protein sequence altering (ie, missense, nonsense, 
frameshift deletion, in-frame deletion, large deletion, and 
duplication) or splice-site variant with an allele frequency 
<1×10−4 in the Genome Aggregation Database.20–22 Genetic 
testing and variant curation as per the American College of 
Medical Genetics and Genomics and Association of Molecular 
Pathology guidelines23 was conducted as described in the 
Methods section in the Data Supplement. All subjects or their 
guardians provided informed consent, and the study was 
approved by the appropriate ethical review boards.
Phenotypic Characterization and 
Measurement of the QT-Interval
Clinical data were collected at each of the participating cen-
ters. We collected a baseline ECG for each patient, preferably 
not during β-blocker use. The QT-interval duration was mea-
sured as previously described (Figure I in the Data Supplement, 
and Methods in the Data Supplement).24 In genotype negative 
patients, a LQTS diagnosis was additionally curated by 2 clini-
cians (NL, RT) and in case of uncertainty, 2 senior LQTS experts 
(AAW, PJS) were consulted. As per international guidelines,5 
we only included genotype negative patients with a LQTS risk 
score≥3.5 or with a resting QTc≥500ms in repeated 12-lead 
ECGs, in the absence of a secondary cause for QT prolongation.
Genome-Wide Array Genotyping, Quality 
Control, and Imputation
We performed genome-wide genotyping for all European 
cases on the Illumina HumanOmniExpress array and for all 
Japanese cases on the Illumina Global Screening Array. 
Genotypic data of 8219 control individuals of European ances-
try and 1671 individuals of Japanese ancestry were obtained 
from different cohorts (Table II in the Data Supplement). 
Quality control,25 imputation and association analysis were 
performed separately in the European and Japanese datas-
ets. All genetic variants were mapped to and reported using 
Genome Reference Consortium Human genome build 37.
After quality control (see Methods in the Data Supplement 
for details), we performed genome-wide imputation using 
Eagle2 phasing, Minimac3 and the Haplotype reference 
consortium (HRCr1.1) panel implemented on the Michigan 
Imputation Server for both the European and Japanese datas-
ets.26 After imputation, only single nucleotide polymorphisms 
(SNPs) with minor allele frequency >0.01 and a Minimac3 
imputation score of R2>0.3 were included in further analyses.
Genome-Wide Association Analysis
We performed genome-wide association analyses to assess the 
role of common variants in LQTS susceptibility (case–control) 
and severity (QTc within the cases). Case–control association of 
alternate allele dosage with LQTS was performed using logis-
tic regression correcting for genotypic principal components 
1 to 10. Quantitative trait analyses for QTc were conducted 
using a linear regression model correcting for age, β-blocker 
use at ECG, LQTS type (KCNQ1 [LQT1], KCNH2 [LQT2], SCN5A 
[LQT3], or genotype negative), sex, and principal components 1 
to 10. Genome-wide association analyses were carried out sep-
arately for the European and Japanese LQTS cohorts, followed 
by meta-analysis using an inverse variance weighted fixed 
effect model, implemented in METAL (version 2011-03-25).27 
Genome-wide statistical significance and suggestive thresholds 
were set to P<5×10−8 and P<1×10−6, respectively. Summary 
statistics were uploaded to FUMA (Functional Mapping and 
Annotation of GWAS) for generation of Manhattan, quantile-
quantile, and regional association plots for risk loci.28
Survival Analyses
Time to life-threatening arrhythmic events (LAE) survival 
analyses were performed in the LQTS cases. Follow-up started 
at birth and stopped at the date of a documented LAE, the 
last visit, or the 41st birthday, whichever came first. LAE 
were defined as out of hospital cardiac arrest, hemodynami-
cally unstable ventricular tachycardia/ventricular fibrillation, 
or appropriate implantable cardioverter-defibrillator therapy. 
The effect of genotype positive versus genotype negative 
status was estimated using Cox proportional hazards regres-
sion with/without adjustment for classic risk factors (ie, sex 
and QTc≥500 ms). To examine possible differences in effect 
of these well-recognized risk factors in genotype positive and 
genotype negative LQTS cases, interactions between these 
risk factors and genotype status were included in the model. 
In addition, puberty and a sex × puberty interaction were 
included to model the modifying effect of puberty on the 
effect of sex. Puberty was included as time-varying covariate 
and the age of puberty was set at 16 years in both sexes (ie, 
during the follow-up period before the age of 16, puberty 
was coded as 0, whereas puberty was coded as 1 during the 
remainder of the follow-up period). Kaplan Meier curves were 
created to illustrate the cumulative event free survival and log 
rank tests were used to compare the survival curves.
Polygenic Risk Scores
For all cases and controls, we calculated a weighted QT poly-
genic risk score (PRSQT) comprising 68 SNPs that had been 
associated with the QT-interval in the general population 
at genome-wide statistical significance, in a study primar-
ily including Europeans.29 All 68 SNPs were included in the 
European dataset analyses whereas only 60/68 SNPs were 
well-imputed and included in the Japanese dataset analyses 
(Table III in the Data Supplement). PRSQT was calculated by 
multiplying the alternate allele dosage by the associated effect 
size (β) in the published QT GWAS for each of the 68 SNPs. 
Then, the PRSQT was normalized to a mean of 0 and standard 
deviation of 1. We used logistic regression to test for associa-
tion of PRSQT with case–control status, correcting for principal 
components 1 to 10. We also used P value thresholding and 
R2 pruning with P values of 5×10−8, 1×10−5, 1×10−4, 1×10−3, 
and 1×10−2 and R2 of 0.2 and 0.1 on summary statistics 
from a European29 and Japanese30 descent general popula-
tion QT-interval GWAS. The resulting 10 models were used to 
calculate a European and Japanese PRSQT. The association of 
PRSQT with LQTS was assessed using a logistic regression for 
the European and Japanese cases separately. The best model 
was selected based on the maximal C-statistic, as recently 
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performed.31 No other covariate was used to avoid model 
overfitting.
The odds ratios (ORs) associated with quartile 2, 3, and 4 
were calculated using the first PRSQT quartile as the reference. 
The association of PRSQT and known QT predictors with QTc 
was performed using a univariable linear regression followed 
by multivariable analysis, including in the final model only 
those variables with a P<0.05 in the univariable analyses. The 
association of PRSQT quartiles with time to LAEs was assessed 
using Cox proportional hazards regression with/without 
adjustment for classic risk factors. Association analyses of 
PRSQT with case–control status, QTc, and time to LAE were 
performed separately in the European and Japanese datasets, 
followed by a fixed-effects model meta-analysis.
Common Variant Heritability
We used the generalized restricted maximum likelihood 
(GREML) approach of GCTA (GCTA-GREML)32 to estimate how 
much of the variance in LQTS susceptibility could be attributed 
to common genetic variants (SNP-based heritability, h2SNP). 
Before heritability estimation, we conducted additional strin-
gent genetic quality control, as previously suggested (Methods 
in the Data Supplement).33 We estimated the SNP-heritability on 
the liability scale assuming a 0.04% prevalence with principal 
components 1-10 as covariates.1 We assessed the robustness of 
heritability estimates from GCTA-GREML using the GREML and 
phenotype-correlation genotype-correlation regression34 analy-
ses implemented in LDAK.35 We estimated h2SNP in the overall 
LQTS and genotype positive LQTS dataset in the both European 
and Japanese ancestries. Because of small sample size we were 
not able to estimate h2SNP in genotype negative patients with 
LQTS using the approaches implemented in GCTA or LDAK.
Genetic Correlation With Other Traits
We used bivariate linkage disequilibrium score regression36 to 
evaluate the genetic correlation between LQTS susceptibility 
(as obtained in the European descent case–control GWAS) and 
other cardiac electric traits,2 namely PR, QRS, QT, heart rate (HR) 
at rest, HR in response to exercise and recovery, and atrial fibrilla-
tion (see Methods in the Data Supplement for origin of summary 
statistics). We used Bonferroni correction to account for multiple 
testing (P=0.05/7=0.0071). We did not constrain the bivariate 
regression intercepts in any of these analyses given the potential 
for (modest) sample overlap and population stratification.
RESULTS
Clinical Characteristics of the Case Cohort
Demographic and clinical characteristics of the unre-
lated LQTS cases are presented in Table IV in the Data 
Supplement separately for the European and Japanese 
datasets and in Table 1 for the combined cohort. We 
included a total of 1781 unrelated patients with LQTS 
of European (n=1344, mean QTc±SD: 484±48ms) and 
Japanese descent (n=437, QTc: 485±49ms). A total of 
1584 cases (89%) were genotype positive, carrying a 
rare variant in KCNQ1 (LQT1, n=800), KCNH2 (LQT2, 
n=661), or SCN5A (LQT3, n=123), while in 197 (11%) 
no disease causing variant was identified (ie, genotype 
negative) despite extensive genetic testing.
The mean QTc interval in genotype negative cases 
was higher in comparison with genotype positive ones 
(500±52ms vs 482±47ms, P=2×10−5) and in genotype 
negative cases a family history of sudden cardiac death 
at <50 years of age in 1st and 2nd degree relatives was less 
frequent compared with genotype positive ones (12.7% 
vs 22.9%, P=0.001). Of the 1584 genotype positive cas-
es, 1333 (84%) carried a pathogenic or likely-pathogenic 
variant according to American College of Medical Genet-
ics and Genomics and Association of Molecular Pathology 
guidelines, and the remainder had a variant of unknown 
significance. The QTc did not significantly differ between 
carriers of variants of unknown significance and those 
with a pathogenic or likely-pathogenic variant (P=0.9).
In total, 429 cases (24%) had an LAE at a median age 
of 28 years (interquartile range, 17 to 46 years), with 
295 cases (17%) having such an event by age 40. LAE-
free survival did not significantly differ between geno-
type negative and positive cases (P=0.8) or between 
European and Japanese cases (P=0.053; Figure 1). In a 
multivariable Cox proportional hazard model, male sex 
(OR 1.9; P=0.004), QTc>500ms (OR 1.8; P=4×10−6) and 
Japanese ancestry (OR 1.4; P=0.03) were independent 
risk factors for LAE (Table V in the Data Supplement). We 
found a significant sex-puberty interaction (P=1×10−6), 
where males were at higher risk of LAE in the prepuber-
tal years but lower risk thereafter (Figure II in the Data 
Table 1. Clinical Characteristics of All Unrelated LQTS Cases
Parameter
Genotype 
Positive (n=1584)
Genotype 
Negative (n=197)
Male, n (%) 584/1584 (37) 76/197 (39)
QTc mean±SD, ms 482±47 500±52
Genotype, n (%)
  KCNQ1 800/1584 (50) —
  KCNH2 661/1584 (42) —
  SCN5A 123/1584 (7.8) —
Syncope, n (%) 722/1584 (46) 75/197 (38)
LAE (OHCA or VF/VT) before age 
41, n (%)
262/1578 (17) 33/196 (17)
  Age at first LAE, median [IQR] 21 [13–29] 26 [16–35]
Treatment during follow-up, n (%)
  Beta-blocker 1169/1487 (79) 124/168 (74)
  ICD 277/1562 (18) 38/172 (22)
  PM 50/1565 (3.2) 11/171 (6.4)
  LCSD 29/1583 (1.8) 1/171 (0.6)
Family history of SCD <50 yr of 
age, n (%)
323/1409 (23) 24/189 (13)
ICD indicates implantable cardioverter-defibrillator; IQR, interquartile 
range; LAE, life-threatening arrhythmic event; LCSD, left cardiac sympathetic 
denervation; OHCA, out-of-hospital cardiac arrest; PM, pacemaker; SCD, 
sudden cardiac death, SD, standard deviation; and VF/VT, hemodynamically 
unstable ventricular fibrillation/tachycardia
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Supplement). The effect of the conventional risk factors 
sex (Pinteraction=0.3) and QTc≥500ms (Pinteraction=0.7) did not 
differ between genotype positive and genotype negative 
cases. Genotype (KCNQ1, KCNH2, SCN5A, or negative) 
significantly affected time to LAE (log-rank test P<0.001; 
Figure III in the Data Supplement). Cases with a rare vari-
ant in KCNQ1 had a lower risk of LAE compared with 
KCNH2, SCN5A, and genotype negative ones (P<0.01 
for all comparisons). None of the other post hoc pairwise 
comparisons reached statistical significance. Time to LAE 
did not differ between cases with a variant of unknown 
significance and those with pathogenic or likely-patho-
genic variant (Figure IV in the Data Supplement).
Case–Control GWAS
We conducted a case–control GWAS separately in Eu-
ropean (1238 cases vs 8219 controls, genomic test 
inflation (λ)=1.024) and Japanese (418 cases vs 1617 
controls, λ=1.034) cases using ancestry-matched con-
trols (Figures V and VI in the Data Supplement), fol-
lowed by transethnic meta-analysis (λ=1.028). This 
uncovered 3 loci reaching the threshold for genome-
wide statistical significance (Table 2, Figure 2, and Fig-
ures VII and VIII in the Data Supplement). The most 
significant association was obtained for rs12143842 
(OR=1.32 [95% CI, 1.21–1.42]; P=1.09×10−11) located 
upstream of NOS1AP (Figure VIIIA in the Data Supple-
ment). The lead SNP at the second locus was located 
in an intron of KCNQ1 (rs179405, OR=1.38 [95% CI, 
1.23–1.54]; P=1.92×10−8; Figure VIIIB in the Data Sup-
plement). At the third locus, the lead SNP, rs17061696 
(OR=1.25 [95% CI, 1.15–1.35]; P=4.33×10−8), was lo-
cated in an intron of KLF12 (Figure VIIIC in the Data 
Supplement). All 3 loci had been previously associated 
with the QT-interval duration, a measure of myocar-
dial repolarization on the ECG, in the general popu-
lation (Table  1).29 The low-frequency missense variant 
in KCNE1, p.Asp85Asn (rs1805128, OR=2.78 [95% CI, 
1.67–3.90]; P=5.31×10−7; Figure VIIID in the Data Sup-
plement) reached the suggestive statistical significance 
threshold in the European case–control analysis. This 
variant, which is rare and not well imputed in the Japa-
nese dataset (minor allele frequency=0.001; R2<0.3), 
has the largest reported effect size among the 68 inde-
pendent SNPs (hereafter referred to as QT-SNPs) previ-
ously associated with QT-interval in the general popula-
tion (7.4ms increase per minor allele).29 Of note, The 
KCNE1-p.Asp85Asn variant had a more pronounced 
effect in genotype negative (OR=7.64 [95% CI, 3.66–
15.95]; P=5.99×10−8) than in genotype positive LQTS 
(OR=2.28 [95% CI, 1.46–3.54]; P=2.59×10−4).
Genetic Overlap Between LQTS and QT-
Interval in the General Population
The identification of SNPs previously associated with QT-
interval in the general population is in line with the fact 
that QT-interval prolongation on the ECG (representing 
prolonged cardiac repolarization) is the central intermedi-
ate phenotype underlying LQTS. In fact, 23 of the 68 QT-
SNPs previously associated with QT-interval in the general 
population, were associated with LQTS at nominal signifi-
cance (ie, P<0.05), while only 4 would be expected under 
the null hypothesis (Table VI in the Data Supplement). We 
observed a strong positive correlation between the effect 
that each of the 68 QT-SNPs had on the QT-interval in the 
general population29 and the risk they conferred for LQTS 
in the current study. This effect was consistent across 
both the European (Figure  3A; R2=0.67; P=2.04×10−17) 
and the Japanese (Figure 3B; R2=0.52; P=1.43×10−10) da-
tasets. Overlap between genetic risk for LQTS and genetic 
determinants of the QT-interval in the general popula-
tion29 was further demonstrated by genome-wide bivari-
ate linkage disequilibrium score regression,36 which de-
tected a significant positive genetic correlation (rg=0.40, 
SE=0.14; P=3.2×10−3) between these phenotypes. No 
significant correlation was found for other cardiac electric 
traits (Figure IX in the Data Supplement).
Analysis of PRSQT in LQTS Disease 
Susceptibility
We then tested the aggregate effect of the 68 QT-
SNPs (PRSQT) on susceptibility to LQTS by means of PRS 
analysis (Table III in the Data Supplement). PRSQT was 
Figure 1. Kaplan-Meier life-threatening arrhythmic event–free survival 
curves stratified by ancestry.
EU indicates European LQTS cases; Geno-, genotype negative LQTS cases; 
Geno+, genotype positive LQTS cases; JP, Japanese LQTS cases; LAE, life-
threatening arrhythmic event (defined as the composite of out of hospital 
cardiac arrest or hemodynamically unstable ventricular tachycardia/arrhythmia; 
and LQTS, long QT syndrome. Log-rank test P=0.3.
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significantly associated with a diagnosis of LQTS in 
the European set, the Japanese set, and in the meta-
analysis of both datasets (Figure 4A and 4C; Table 3; 
meta-analysis β=0.34, SE=0.03; P=1.1×10−38, hetero-
geneity P=0.15). Similar results were obtained when 
we excluded common variants located at the known 
Mendelian LQTS loci from the PRS (Table VII in the Data 
Supplement). Ten different PRS derived by the pruning 
and thresholding method on summary statistics from 
the European descent general population QT-interval 
GWAS did not significantly outperform the PRSQT in dis-
criminating case–control status (Table VIIIA in the Data 
Supplement). Similarly, Japanese ancestry-specific PRS 
derived from summary statistics of a small Japanese 
Table 2. Significant Loci in LQTS Case–Control GWAS
Lead SNP
    Meta-Analysis European Japanese  
GRCh37
Alternative
Allele
Reference
Allele
Closest 
Gene OR 95%CI P
AAF 
(Controls
/Cases) OR P
AAF 
(Controls
/Cases) OR P
Effect 
on QT 
(ms)*
rs12143842 1:162033890 T C NOS1AP 1.31 1.21–1.42 1.09E−11 0.26/0.32 1.29 7.34E−08 0.38/0.47 1.41 2.13E−05 3.5
rs179405 11:2525395 A G KCNQ1 1.38 1.23–1.54 1.92E−08 0.14/0.17 1.34 4.03E−06 0.10/0.14 1.63 5.42E−04 1.9†
rs17061696 13:74511991 C G KLF12 1.25 1.15–1.35 4.33E−08 0.37/0.43 1.27 8.91E−08 0.19/0.21 1.16 1.43E−01 0.58
AAF indicates alternative allele frequency; GRCh37, genomic position on build GRCh37; and OR, odds ratio per alternative allele. 
*QT increase (in ms) per alternative allele in the general population.
†The lead SNP at the KCNQ1 locus (rs179405) is in linkage disequilibrium with rs7122937 (R2=0.497) which had been previously associated with QT-interval in the general 
population (1.9 ms increase per risk allele).
Figure 2. Manhattan plot of long QT syndrome case–control meta-analysis.
Manhattan plot displaying the base-pair position of each of the tested single nucleotide polymorphisms (SNPs; each dot represents an individual SNP) along the 
chromosomes on the x axis and the corresponding −log10 transformed association P value on the y axis. The association P values from the meta-analysis of the 
2 genome-wide association studies conducted separately in European and Japanese cases and controls, respectively, are displayed. The upper and lower dashed 
lines indicate the genome-wide significance (P<5×10–8) and suggestive significance (P<1×10 –6) thresholds, respectively. SNPs at genomic regions that reached the 
genome-wide or suggestive significance thresholds, are marked in red, whereas SNPs from other regions are marked in black or grey. The association for variant 
rs1805128 (KCNE1:p.Asp85Asn) is solely driven by the European analysis because it is not well imputed and rare (R2<0.3. minor allele frequency=0.001) in the 
Japanese dataset.
Lahrouchi et al Genome-Wide Association Study in Long QT Syndrome
July 28, 2020 Circulation. 2020;142:324–338. DOI: 10.1161/CIRCULATIONAHA.120.045956330
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
QT-interval GWAS30 had less discriminative accuracy in 
the Japanese case–control dataset compared with the 
European-derived PRSQT, likely because of the small size 
of the Japanese QT-interval GWAS (Table VIIIB in the 
Data Supplement).
We next explored whether the genetic architecture 
of genotype negative patients (ie, those lacking a rare 
variant after extensive genetic testing of the estab-
lished LQTS disease genes) differed from that of gen-
otype positive patients. This was done by comparing 
PRSQT between both groups, uncovering a significantly 
higher PRSQT in genotype negative patients, pointing to 
a more prominent role for common variants in disease 
susceptibility in these patients. This effect was con-
sistently observed in both the European (P=5.1×10−6, 
Figure  4B) and the Japanese (P=2.0×10−3, Figure  4D) 
datasets (Table  3). Similar results were obtained in a 
sensitivity analysis correcting for QT-interval, ensuring 
that enrichment of QT prolonging alleles in the geno-
type negative patients was not driven by differences in 
QT-interval (P=7.4×10−5 in Europeans; P=2.6×10−3 in 
Japanese, Table  3). These associations remained sta-
tistically significant when we restricted the analysis to 
patients with a pathogenic or likely-pathogenic variant 
according to American College of Medical Genetics 
and Genomics and Association of Molecular Pathology 
guidelines (ie, excluding cases with a rare variant of un-
known significance; Methods in the Data Supplement 
and Tables IX and X in the Data Supplement). Increas-
ing PRSQT quartiles were associated with a significantly 
higher disease susceptibility for genotype negative 
LQTS compared with the lowest quartile (Figure 5; Table 
XI in the Data Supplement). It is notable that, using a 
PRSQT percentile threshold of 80, 90, and 95, individuals 
above the threshold compared with those below have 
an OR (95%CI) of 2.9 (2.2–4.0), 4.1 (2.9–5.8), and 5.7 
(3.9–8.4), respectively, for genotype negative LQTS. Of 
interest, the higher PRSQT in genotype negative patients 
compared with genotype positive patients was reflect-
ed by the larger difference in PRSQT between genotype 
negative patients versus controls (Table 3; meta-analy-
sis β=0.735, SE=0.074; P=2.24×10−23) compared with 
genotype positive versus controls (Table 3; meta-analy-
sis β=0.294, SE=0.028; P=1.09×10−25).
Common Variant Heritability of LQTS
To evaluate the proportion of variance in LQTS suscep-
tibility explained by common genetic variants (h2SNP) we 
used GCTA-GREML.32,37 Assuming a disease prevalence 
of 0.04%,1 the SNP heritability estimate on the liabil-
ity scale was h2SNP=0.148 (SE=0.019 [95% CI, 0.111–
0.185]; P=5.0×10−18) in the overall European LQTS da-
taset. h2SNP was similar when the analysis was restricted 
to genotype positive patients with LQTS. Similar results 
were also observed in the Japanese dataset and when 
using the phenotype-correlation genotype-correlation 
regression34 and the GREML estimation implemented 
in LDAK,35 as well as when we restricted h2SNP analyses 
to only patients with a pathogenic or likely-pathogenic 
variant (Table XII in the Data Supplement).
Association Analyses of Single SNPs and 
PRSQT With LQTS Severity
To identify genetic modifiers of disease severity we con-
ducted a GWAS for QT-interval within the LQTS cases 
which did not uncover any genome-wide significant 
Figure 3. Correlation of effect size of QT-associated single nucleotide polymorphisms with their effect size in long QT syndrome genome-wide as-
sociation study.
The x axis represents the effect estimates from the QT-interval genome-wide association study (GWAS) conducted in the general population (milliseconds per 
alternative allele) and the y axis the effect of each of these QT-interval associated alleles on disease risk of long QT syndrome (LQTS; [Ln(OR)]) in the European (A) 
and Japanese (B) datasets. All 68 SNPs associated with QT in the general population were assessed in Europeans, whereas 60 SNPs were properly imputed in the 
Japanese dataset. In the LQTS-GWAS meta-analysis, 23/68 SNPs previously associated with the QT in the general population reached nominal significance (see 
Table VI in the Data Supplement). Loci that reached genome-wide significance in the LQTS case–control transethnic meta-analysis NOS1AP-rs12143842, KCNQ1-
rs179405, KLF12-rs728926, and KCNE1-rs1805128 are identified with text.
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loci (Figure X in the Data Supplement). None of the 
68 SNPs previously associated with QTc in the gen-
eral population29 showed association with QTc after 
Bonferroni correction. PRSQT showed a weak positive 
correlation with QTc in the European cases (correla-
tion coefficient [r]=0.06; P=0.042; Figure XI in the 
Data Supplement). In a multivariable linear regression 
model including clinical covariates associated with QTc 
(age at ECG recording, LQTS type, and sex), PRSQT was 
not significantly associated with QTc (Table XIII in the 
Data Supplement). Similarly, in a subanalysis restricted 
to probands (comprising 97% of the total of unrelated 
LQTS cases) using the multivariable linear regression 
model, PRSQT was not significantly associated with 
QTc (data not shown). In exploratory subgroup analy-
ses, PRSQT was independently associated with QTc in 
KCNH2 rare variant carriers but not in KCNQ1 rare 
variant carriers (Table XIII in the Data Supplement). 
This result was not replicated in the Japanese LQTS 
dataset. PRSQT was not significantly associated with 
time to LAE in neither Europeans nor Japanese cases 
(Figure XII in the Data Supplement).
DISCUSSION
Our findings establish an important role for common 
genetic variation in LQTS susceptibility and support a 
complex (polygenic) architecture in genotype negative 
LQTS. Case–control GWAS identified 3 genome-wide 
significant risk loci near NOS1AP, KCNQ1, and KLF12. 
Heritability analysis demonstrated that ≈15% of LQTS 
disease liability is attributable to common genetic varia-
tion. PRS analysis testing the aggregate effect of SNPs 
previously associated with QT-interval in the general 
population (PRSQT) identified a higher PRSQT in LQTS 
cases compared with controls and higher PRSQT in gen-
otype negative versus genotype positive LQTS.
Shared Genetics of LQTS and QT-Interval 
in the General Population
The case–control GWAS uncovered 3 genetic LQTS sus-
ceptibility loci at genome-wide statistical significance 
near NOS1AP, KCNQ1, and KLF12, and 1 missense 
variant in KCNE1 at the suggestive threshold (Figure 2). 
Figure 4. Distribution of QT polygenic score in controls, long QT syndrome, and genotype positive and negative subgroups.
The x axis represents the QT polygenic score (PRSQT) in the European (A and B; blue) and Japanese (C and D; red) long QT syndrome (LQTS) case–control datasets. 
In A and C, all LQTS cases are grouped regardless of whether they are genotype positive or negative, whereas in B and C, cases have been stratified in genotype 
positive and negative LQTS subgroups. PRSQT was normalized to a mean of 0 and standard deviation of 1. Reported P values refer to the effect of PRSQT in a logistic 
regression correcting for the first 10 principal components. *Refers to case–control association. Comparison of PRSQT between genotype negative versus genotype 
positive LQTS uncovered a significantly higher PRSQT in genotype negative patients. This effect was consistently observed in both the European (P=5.1×10
−6) and 
the Japanese (P=2.0×10−3) patients (Table 3).
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The association of SNPs at KCNQ1 points to the involve-
ment of common variants acting alongside rare variants 
in these genes in mediating disease susceptibility, akin 
to what was previously reported for common and rare 
variation in and around the SCN5A gene in Brugada 
syndrome.16 All 4 risk loci had been previously impli-
cated in genetic control of the QT-interval by GWAS in 
the general population.29 For the 68 SNPs associated 
with QT-interval in the general population, we noted 
a strong positive correlation between their effect on 
QT-interval (obtained in the general population) and 
their OR for LQTS susceptibility, indicating, as expected, 
that the larger the effect a SNP has on the QT-interval, 
the more it increases LQTS susceptibility (Figure 3). The 
strong genetic correlation between LQTS susceptibil-
ity and QT-interval in the general population provides 
quantitative support for genetic overlap (Figure IX in 
the Data Supplement).
The association with the highest effect in the case–
control GWAS was found for the p.Asp85Asn missense 
variant in KCNE1 (rs1805128). This variant increased 
susceptibility for LQTS in the overall cohort but had a 
more prominent effect in genotype negative LQTS with 
an OR of ≈7 versus an OR of 2 in genotype positive pa-
tients. This variant has an allele frequency of ≈1.2% in 
non-Finnish Europeans and ≈0.5% in East Asians, and 
has the largest effect size on the QT in the general (Eu-
ropean descent) population (7.42 ms per minor [Asn] 
allele).29 It has been shown to be enriched in patients 
with drug-induced torsades de pointes.38
Genetic Architecture of Genotype 
Positive LQTS
LQTS has traditionally been viewed as a monogenic dis-
order mostly attributed to a rare variant with a drastic 
effect on ion channel function. We now demonstrate 
that a considerable extent (≈15%) of disease liability is 
attributable to common genetic variation. In genotype 
positive LQTS families, where the penetrance of patho-
genic variants may be low for certain variants,8 the 
contribution of common variants to disease susceptibil-
ity may also contribute to variable disease penetrance. 
It has been well established that LQTS probands have a 
longer QT-interval and greater arrhythmic risk compared 
with family members carrying the same variant.7,13,39 
This observed increased penetrance in probands may 
result from a greater burden of common QT-prolonging 
variants compared with other, less-severely affected, or 
unaffected mutation-carriers. However, because this 
study comprised only unrelated patients, this remains 
to be determined. Whether the PRSQT could discrimi-
nate between affected versus unaffected mutation car-
rier family members is intuitively appealing but remains 
to be formally demonstrated.
Genotype Negative LQTS, A Polygenic 
Subtype of LQTS?
PRS analysis, testing the aggregate effect of SNPs previ-
ously associated with QT-interval in the general popula-
tion (PRSQT), identified a higher PRSQT in genotype nega-
tive versus genotype positive patients. This observation 
points to genotype negative LQTS, comprising ≈10% of 
patients with LQTS, as a polygenic subtype of the dis-
order where the underlying etiology involves, at least in 
part, a high burden of common QT prolonging alleles. 
As such, genetic susceptibility in genotype negative 
patients may not be determined to a large extent by 
1 strong genetic factor as occurs in genotype positive 
patients but results from the accumulation of multiple 
variants (polygenic inheritance). The lower rate of fam-
ily history of sudden cardiac death in genotype negative 
patients with LQTS is in line with polygenic inheritance. 
Our observations corroborate findings in other herita-
ble phenotypes, such as familial hypercholesterolemia, 
where patients without a disease-causing variant in the 
LDLR, APOB, and PCSK9 genes have a higher PRS based 
on low-density lipoprotein modulating variants in com-
parison with those with rare familial hypercholesterol-
emia causing genetic variants.40 As such, the accumula-
tion of multiple discrete common variants may confer 
Table 3. Association of QT Polygenic Score With Long QT Syndrome
Association Analysis 
of PRSQT
European Japanese Meta-analysis
n β SE P n β SE P n β SE P
All LQTS vs Controls 1238/ 8219 0.322 0.030 4.93E−26 418/ 1671 0.412 0.055 6.16E−14 1656/9890 0.343 0.0263 1.08E−38
Genotype positive LQTS 
vs Controls
1115/ 8219 0.277 0.032 3.47E−18 356/ 1671 0.348 0.058 2.52E−09 1471/ 9890 0.294 0.028 1.09E−25
Genotype negative 
LQTS vs Controls
123/ 8219 0.733 0.090 3.74E−16 62/ 1671 0.740 0.129 1.19E−08 185/9890 0.735 0.0738 2.24E−23
Genotype negative vs
Genotype positive LQTS
123/ 1115 0.447 0.098 5.05E−06 62/356 0.401 0.129 2.01E−03 185/1471 0.430 0.078 3.54E−08
Genotype negative vs
Genotype positive LQTS*
123/ 1115 0.409 0.103 7.36E−05 62/356 0.393 0.130 2.62E−03 185/1471 0.403 0.0807 6.05E−07
β indicates regression coefficient; n, sample size (cases/controls); P, P-value; PRSQT, QT polygenic score; and SE, standard error.
*Correcting for QTc.
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risk similar to a monogenic mutation. This was recently 
demonstrated for common disorders such as coronary 
artery disease and atrial fibrillation, where individuals 
at the upper extreme of the PRS distribution had a risk 
of developing the disease reportedly comparable with 
carriers of a monogenic mutation.31 The overlap in the 
PRSQT distributions among genotype negative LQTS cas-
es and controls (Figure 4) suggests that other factors 
are involved, possibly including low-frequency genetic 
variants with intermediate effect sizes as well as other 
common variants with smaller effect sizes.
In addition to providing insight into the genetic ar-
chitecture of genotype negative LQTS, we here also de-
scribe for the first time the natural history in these pa-
tients. All ≈200 genotype negative patients with LQTS 
met diagnostic criteria for definite LQTS (ie, QTc>500ms 
or LQTS score≥3.5) and underwent sequencing of the 
unequivocal nonsyndromic LQTS genes. Genotype neg-
ative patients with LQTS had a higher QTc in compari-
son with patients with LQT1–3 but similar event-free 
survival as their genotype positive counterparts (Fig-
ure  1). The effect of established clinical risk factors, 
for example sex and QTc-duration, did not significantly 
differ between genotype positive and negative (no in-
teraction effect) suggesting they may also be used to 
stratify risk of events in genotype negative LQTS.
Common Variants Do Not Contribute to 
LQTS Severity Within Probands
We sought to identify genetic modifiers of LQTS. In 
contrast to the case–control GWAS, GWAS for QTc and 
arrhythmic events within the unrelated LQTS cases did 
not uncover any genome-wide significant locus. PRSQT 
was also not significantly associated with QTc nor with 
the occurrence of events. At first glance, this may seem 
contradictory to previous studies in LQTS that demon-
strated a modulatory effect of SNPs at NOS1AP on the 
QTc and arrhythmic events,10,11,13 as well as a study in 
the general population that showed a modulatory ef-
fect of PRS derived from previous GWAS on QT-inter-
val.41 For example, a study we previously conducted in 
patients with LQT2 uncovered strong associations with 
large effect sizes (>12 ms/allele) for SNPs at NOS1AP.13 
An important difference however, is that the current 
study did not include family members but only 1 pa-
tient per family (97% probands), whereas the previous 
studies considered both probands and genotype posi-
tive relatives. Conceptually, inclusion of both probands 
and relatives results in greater variation in QTc and is 
thus expected to increase statistical power for detection 
of modulatory effects. Moreover, the different rare vari-
ants in the patients we studied here are associated with 
biophysical defects of varying severity. As such, they are 
also expected to contribute to interindividual variability 
which is difficult to account for. For instance, patients 
with LQT2 with pore-region variants are known to be 
more severely affected than other patients with LQT2.42 
Indeed, in a subanalysis, restricted to European patients 
with LQT2, where we accounted for the mutation loca-
tion (pore versus nonpore), we detected an association 
of PRSQT with QTc. In sum, our data show that com-
mon variants do not affect disease severity across all 
probands studied. Further studies are needed to explore 
their predictive role in family members.
Potential Clinical Implications
In genotype negative LQTS, disease susceptibility esti-
mation for relatives does not follow a Mendelian pat-
tern. In our cohort, a positive family history of sudden 
cardiac death was less often observed in genotype 
negative individuals compared with genotype posi-
tive ones, suggesting that risk for family members in 
genotype negative patients may be lower. Polygenicity 
in genotype negative individuals implies that risk is not 
Figure 5. Increasing long QT syndrome risk with increasing QT poly-
genic score quartiles.
Odds ratio (OR) for genotype negative long QT syndrome (LQTS; filled circles) 
and 95% CI (vertical bars) associated with each QT polygenic score (PRSQT) 
quartile taking the first PRSQT quartile as the reference. Data shown correspond 
to a meta-analysis of effects computed separately in the European and Japanese 
datasets. P values refer to comparison of each quartile against the first quartile.
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primarily attributable to 1 genetic factor inherited from 
1 of the biological parents as is the case for autosomal 
dominant LQTS. In such cases, cascade screening may 
necessitate clinical evaluation of both maternal and pa-
ternal family members. Future clinical utility of genetic 
testing based on polygenic inheritance necessitates the 
availability of polygenic risk scores with high discrimi-
native capacity. The discriminative capacity of a PRS 
based on QT modulating SNPs is expected to improve 
as knowledge concerning variants that modulate the 
QT-interval become known, for example through larg-
er GWAS studies, or by combining it with nongenetic 
modifiers. In a recent study, a PRS based on 61 QT-SNPs 
(a subset of the 68 QT modulating SNPs included in 
the PRSQT used herein) explained a substantial propor-
tion of QT-interval response to QT-prolonging drugs in 
a trial of 3 QT-prolonging drugs conducted in healthy 
individuals, as well as risk of torsade de pointes in a 
case–control study.43 This provides further support to a 
liability threshold model whereby multiple factors, ge-
netic and nongenetic, impact on cardiac repolarization 
and determine arrhythmic risk. In this respect, calcula-
tion of PRSQT for the purpose of preventive avoidance 
of QT-prolonging drugs may be desirable for relatives of 
genotype negative LQTS. It is clear that further studies 
are needed to address how testing for polygenic sus-
ceptibility may become clinically useful.
Study Limitations
Although in genotype negative patients with LQTS we 
performed sequencing of the coding region of nonsyn-
dromic LQTS genes, this may have missed copy number 
variation or disease-causing variants in the noncoding 
region44 of established genes as well as mutations in 
yet unknown disease genes. This may have blunted the 
differences between genotype negative and genotype 
positive patients and thus would not affect the study 
conclusions. Despite being the largest international da-
taset of unrelated patients with LQTS published to date, 
the study had limited statistical power to detect lower 
effect associations at GWAS significance threshold. 
The prespecified design of meta-analyzing European 
and Japanese GWAS may also miss disease loci with 
differences in haplotype structure among European 
and East Asian chromosomes. Nonetheless, GWAS in 
separate ancestries did not detect any association at 
GWAS threshold. Last, studies in larger patient sets are 
required to further refine our understanding of the ge-
netic architecture underlying LQTS in genotype nega-
tive patients.
Conclusions
This work establishes an important role for common 
genetic variation in susceptibility to LQTS. Common 
genetic variation affecting the QT-interval in the general 
population contributes to disease susceptibility in both 
genotype positive and genotype negative LQTS. The 
role of common variants is predominant in genotype 
negative LQTS, suggesting that the latter may consti-
tute a polygenic form of LQTS. Increasing burden of QT-
prolonging common variants (eg, PRSQT) is associated 
with higher susceptibility for LQTS but is not associated 
with disease severity within LQTS probands. Further 
studies are needed to assess the role of polygenic risk 
within LQTS families.
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